EUVIMEDEUVIMED entdecken
VergleichsstudieOpen Access · CC BY 4.0

Superior Clinical and Economic Value of IL ‐23 Inhibitors Versus Adalimumab Biosimilars in Plaque Psoriasis

Gennaro Marco Falco iD, Elena Ippoliti iD, Niccolò Gori, Giacomo Caldarola iD, Clara De Simone, Nicoletta Di Giorgi, Paulo Gabriel Longo, Marco Galluzzo, Luca Bianchi, Lorenzo Marcelli, Marina Talamonti, Maria Vittoria Cannizzaro iD und 2 weitere

International Journal of Dermatology · 2026

DOI: 10.1111/ijd.70371 ↗

Kurz gefasst

Vergleichsstudie in der Zeitschrift International Journal of Dermatology, 2026. Verfasst von Gennaro Marco Falco und 13 weiteren Autor:innen. Beteiligte Einrichtung: Dermatologia, Dipartimento Universitario di Medicina e Chirurgia Traslazionale, Università Cattolica del Sacro Cuore, Rome, Italy. Hauptthemen laut MEDLINE: Psoriasis, Adalimumab, Biosimilar Pharmaceuticals, Interleukin-23. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 23 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

In recent years, the introduction of interleukin (IL)‐23 inhibitors has revolutionized psoriasis treatment, allowing the majority of patients to achieve a long‐term, complete clinical control of the disease. Nevertheless, there are no real‐world studies exploring the cost benefit ratio of these new drugs compared to the currently most prescribed therapies as adalimumab biosimilars.

Methods

We performed a retrospective study to evaluate the clinical effectiveness, measured as Psoriasis Area and Severity Index (PASI)90‐number needed to treat (NNT) and the cost‐effectiveness of IL‐23 inhibitors (guselkumab, risankizumab, tildrakizumab) in patients with moderate to severe psoriasis as compared to adalimumab biosimilars (imraldi, hyrimoz, yuflima, and amgevita). Assessments were performed at Weeks 16 and 52.

Results

Our analysis included 616 patients with moderate to severe psoriasis who had been treated with adalimumab biosimilars or an anti‐IL‐23 inhibitor for at least 16 weeks. Overall, IL‐23 inhibitors were shown to be more effective compared to adalimumab biosimilars, with significantly lower NNT. Risankizumab achieved the highest PASI90 response rates, whereas guselkumab had the most favorable incremental cost per PASI90 responder at Weeks 16 and 52.

Conclusions

Our study highlights the substantial clinical benefit of IL‐23 inhibitors over adalimumab biosimilars, with guselkumab as the more cost‐effective option than the other IL‐23 inhibitors for the real‐world management of moderate‐to‐severe psoriasis. image

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

PsoriasisAdalimumabBiosimilar PharmaceuticalsInterleukin-23HumansRetrospective StudiesAntibodies, Monoclonal, HumanizedFemaleMaleSeverity of Illness IndexCost-Benefit AnalysisAntibodies, MonoclonalMiddle AgedAdultTreatment Outcome

Stichwörter der Autor:innen

NNTPASI90adalimumabanti‐IL‐23psoriasis

Substanzen

AdalimumabAntibodies, Monoclonal, HumanizedBiosimilar PharmaceuticalsInterleukin-23tildrakizumabAntibodies, Monoclonalguselkumabrisankizumab

Autor:innen und Institutionen

  • Dermatologia, Dipartimento Universitario di Medicina e Chirurgia Traslazionale, Università Cattolica del Sacro Cuore, Rome, Italy.
  • UOC Dermatologia, Dipartimento di Scienze Mediche e Chirurgiche, Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, Italy.
  • Real World Data Facility, Gemelli Generator, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Rome, Italy.
  • Department of Systems Medicine, University of Rome Tor Vergata, Rome, Italy.
  • Dermatology Unit, Fondazione Policlinico Tor Vergata, Rome, Italy.
  • Immunology Research Core Facility, Gemelli Science and Technology Park (GSTeP), Fondazione Policlinico Universitario A. Gemelli-IRCCS, Rome, Italy.

ORCID-Profile: Gennaro Marco Falco, Elena Ippoliti, Giacomo Caldarola, Maria Vittoria Cannizzaro, Ketty Peris

Zitieren

APA

Falco, G. M., Ippoliti, E., Gori, N., Caldarola, G., De Simone, C., Di Giorgi, N., Longo, P. G., Galluzzo, M., Bianchi, L., Marcelli, L., Talamonti, M., Cannizzaro, M. V., Di Nardo, L., & Peris, K. (2026). Superior Clinical and Economic Value of IL ‐23 Inhibitors Versus Adalimumab Biosimilars in Plaque Psoriasis. International Journal of Dermatology. https://doi.org/10.1111/ijd.70371

Vancouver

Falco GM, Ippoliti E, Gori N, Caldarola G, De Simone C, Di Giorgi N, et al. Superior Clinical and Economic Value of IL ‐23 Inhibitors Versus Adalimumab Biosimilars in Plaque Psoriasis. International Journal of Dermatology. 2026. doi:10.1111/ijd.70371

BibTeX
@article{Falco2026,
  author = {Falco, Gennaro Marco and Ippoliti, Elena and Gori, Niccolò and Caldarola, Giacomo and De Simone, Clara and Di Giorgi, Nicoletta and Longo, Paulo Gabriel and Galluzzo, Marco and Bianchi, Luca and Marcelli, Lorenzo and Talamonti, Marina and Cannizzaro, Maria Vittoria and Di Nardo, Lucia and Peris, Ketty},
  title = {Superior Clinical and Economic Value of IL ‐23 Inhibitors Versus Adalimumab Biosimilars in Plaque Psoriasis},
  journal = {International Journal of Dermatology},
  year = {2026},
  doi = {10.1111/ijd.70371}
}
Kostenlos starten →